Our findings support further exploration of pharmacologic inhibition of CLK1 as a potential new treatment for obesity associated diabetes, beyond oncology, Duchenne muscular dystrophy and Alzheimer’s disease. This evidence concerns the gene CLK1 and obesity due to melanocortin 4 receptor deficiency.